267 related articles for article (PubMed ID: 9530363)
1. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Tomura A; Kuroiwa S; Okada M; Abe F
Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
[TBL] [Abstract][Full Text] [Related]
2. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Zaccheo T; Giudici D; di Salle E
Prostate; 1997 Feb; 30(2):85-91. PubMed ID: 9051146
[TBL] [Abstract][Full Text] [Related]
3. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
Donn F; Becker H; Klosterhalfen H; Klein H
Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
[TBL] [Abstract][Full Text] [Related]
4. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
5. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Sumiyoshi Y; Hashine K; Kuwahara M; Aki M; Yamamoto A; Akazawa S; Takenaka A
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581
[TBL] [Abstract][Full Text] [Related]
6. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
7. [Total androgen blockade--concept, theory, method and clinical application].
Ozono S; Hirao Y
Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
Zaccheo T; Giudici D; di Salle E
Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
10. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Tsushima T; Nasu Y; Saika T; Maki Y; Noda M; Suyama B; Yamato T; Kumon H
Urol Int; 2001; 66(3):135-9. PubMed ID: 11316974
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
12. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Kung TT; Mingo GG; Siegel MI; Watnick AS
Prostate; 1988; 12(4):357-63. PubMed ID: 3134647
[TBL] [Abstract][Full Text] [Related]
13. Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.
Brandes LJ; Queen GM; LaBella FS
Clin Cancer Res; 1997 Aug; 3(8):1357-61. PubMed ID: 9815819
[TBL] [Abstract][Full Text] [Related]
14. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
[TBL] [Abstract][Full Text] [Related]
16. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats.
Imada S; Akaza H; Ami Y; Koiso K; Ideyama Y; Takenaka T
Eur Urol; 1997; 31(3):360-4. PubMed ID: 9129932
[TBL] [Abstract][Full Text] [Related]
17. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and pure antiandrogenic properties of flutamide.
Labrie F
Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
[TBL] [Abstract][Full Text] [Related]
19. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L
Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
[TBL] [Abstract][Full Text] [Related]
20. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
Almeida OP; Waterreus A; Spry N; Flicker L; Martins RN
Psychoneuroendocrinology; 2004 Sep; 29(8):1071-81. PubMed ID: 15219659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
